KEI Comments Regarding NIH Exclusive License to Paz Pharmaceuticals for Cancer Treatment

On July 7, 2020, Knowledge Ecology International (KEI) submitted comments to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fenoterol and Certain Fenoterol Analogues for the… Continue Reading

Joint Comments Regarding NIH Exclusive License to Ziopharm Oncology for Cell Therapy

(Update: The NIH provided a response to our comments on July 16, 2020) On July 6, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment submitted joint comments regarding the National Institutes of Health’s (NIH) proposed exclusive license… Continue Reading

The European Parliament calls on the European Commission and the Member States to formally support the COVID-19 Technology Access Pool (C-TAP)

On Friday, 10 July 2020, the European Parliament adopted a resolution entitled, The EU’s public health strategy post-COVID-19, by 526 votes to 105 and 50 abstentions. This resolution paves the way for the creation of a European Health Union and… Continue Reading

KEI receives seven new contracts for COVID 19 research from BARDA and DOD, including five using “Other Transactions Authority” that weaken or eliminate Bayh-Dole and FAR Safeguards

KEI has a number of outstanding requests under the United States Freedom of Information Act (FOIA) for contracts related to biomedical innovations to control or treat the COVID-19 pandemic. On Thursday, June 25, and Friday, June 26, we received a… Continue Reading

Joint Comments on Two NIH Exclusive Licenses to CAR Therapy to Vor Biopharma and Senti Bio

On June 15, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatments (UACT) submitted joint comments to the National Institutes of Health regarding two prospective exclusive patent licenses: “Prospective Grant of an Exclusive Patent License: Development and… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License to Retargeted Therapeutics for Cancer Treatment

Update: The NIH sent a response to our comments, available here. The response fails to address the glaring lack of information available regarding Retargeted Therapeutics. On June 8, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT)… Continue Reading

Senate Foreign Relations Committee questions State Department, USAID, and HHS on COVID-19 and U.S. International Pandemic Preparedness, Prevention, and Response

On Thursday, 18 June 2020, the Senate Foreign Relations Committee convened a hearing on COVID-19 and U.S. International Pandemic Preparedness, Prevention, and Response. The witnesses called to provide testimony included: 1) James L. Richardson, Director, Office of Foreign Assistance, U.S.… Continue Reading